5-Amino-1MQ vs tesamorelin compared: how these two metabolic research compounds differ in mechanism, dosing, FDA status, and reported effects.
5-Amino-1MQ and tesamorelin are not the same kind of compound, and they are not interchangeable. 5-Amino-1MQ is a small-molecule NNMT inhibitor sold for research use, while tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that is FDA-approved as Egrifta for HIV-associated lipodystrophy. The practical difference is that tesamorelin has human trial data and a prescription pathway, while 5-Amino-1MQ has only preclinical data and no approved human use.
What Is 5-Amino-1MQ?
5-Amino-1MQ is a small synthetic molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat cell metabolism. Researchers study it because NNMT activity tends to run higher in the adipose tissue of people with obesity, and blocking it appears to change how fat cells store and use energy.
It is often grouped with peptides in marketing copy, but 5-Amino-1MQ is not a peptide. It is a low-molecular-weight compound, which is why it is typically sold as an oral capsule or powder rather than a lyophilized vial.
All published metabolic data on 5-Amino-1MQ comes from rodent studies. No completed human clinical trials establish its safety profile, dosing, or effectiveness.
What Is Tesamorelin?
Tesamorelin is a 44-amino-acid peptide that mimics growth hormone-releasing hormone. It binds GHRH receptors in the pituitary gland and prompts the body to release its own growth hormone in a pulsatile pattern.
The FDA approved tesamorelin under the brand name Egrifta in 2010 to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy. It is given as a daily subcutaneous injection and is not approved for general weight loss or cosmetic fat reduction.
Trials in that specific patient population showed measurable reductions in visceral adipose tissue along with changes in IGF-1 levels. Those results do not automatically transfer to healthy adults using the drug off-label.
Head-to-Head Comparison
| Feature | 5-Amino-1MQ | Tesamorelin |
|---|---|---|
| Compound class | Small-molecule NNMT inhibitor | Synthetic GHRH peptide analog |
| Primary mechanism | Blocks NNMT inside fat cells | Stimulates pituitary GH release |
| FDA status | Not approved for human use | Approved (Egrifta, 2010) |
| Approved indication | None | Visceral fat in HIV-associated lipodystrophy |
| Typical route | Oral capsule or powder | Subcutaneous injection |
| Human data | None published | Multiple controlled trials |
| Prescription required | No (sold as research chemical) | Yes |
Mechanism: Two Very Different Pathways
5-Amino-1MQ works inside the cell. It blocks NNMT, which raises available NAD+ precursors and shifts fat cells toward a leaner metabolic profile in animal models. That effect is local to metabolic tissue rather than hormonal.
Tesamorelin works at the top of the endocrine chain. It stimulates growth hormone release, which then raises IGF-1 and drives lipolysis, particularly in visceral fat. Because it acts on the hormone axis, it can also affect appetite, fluid balance, blood sugar, and joint tissue.
5-Amino-1MQ targets an enzyme inside fat cells, while tesamorelin targets the pituitary hormone axis, so the two compounds are not substitutes for one another.
Dosing and Administration
Route is the most visible difference. Tesamorelin is injected subcutaneously once daily at a labeled dose of 1 mg or 2 mg depending on the formulation, usually in the evening. 5-Amino-1MQ is typically taken orally, with research protocols describing 100–150 mg per day, though no human dose has ever been validated.
People comparing 5-amino-1mq oral vs injection usually ask whether absorption differs. Oral capsules are far more convenient, while subcutaneous injection bypasses first-pass metabolism but has almost no published pharmacokinetic data for this molecule.
The same logic applies to 5-amino-1mq capsules vs injection. Most suppliers treat capsules as the default format and offer injectable versions as a niche option with no established human profile.
Any number quoted online is extrapolated from mouse studies, not from controlled human trials, so no dose can be described as proven.
Where These Compounds Fit in the Research Landscape
Both agents sit in a crowded category of metabolic and fat-loss research compounds. People evaluating slu-pp-332 vs 5-amino-1mq are usually comparing two non-peptide small molecules, while mots-c vs 5-amino-1mq contrasts a mitochondrial-derived peptide with an enzyme inhibitor.
Tesamorelin also gets compared with other growth hormone-related peptides. A frequent search is aod 9604 vs tesamorelin, which sets a GHRH fragment marketed for fat loss against the full GHRH analog that carries FDA approval.
Only one of those two compounds has approved human labeling, and that distinction matters more than any anecdotal report or before-and-after photo.
Safety, Legality, and Sourcing
- Tesamorelin is a prescription drug in the US and carries warnings about increased IGF-1, injection-site reactions, fluid retention, and possible effects on blood sugar and pituitary function.
- 5-Amino-1MQ is sold as a research chemical, is not required to meet pharmaceutical purity standards, and is not intended for human consumption.
- Anyone with diabetes, a cancer history, or a pituitary condition should talk with a healthcare professional before considering either compound.
5-Amino-1MQ is not FDA-approved for human use in the United States, and tesamorelin is approved only for HIV-associated lipodystrophy. That regulatory gap is the single biggest difference between the two.
Bottom Line
Judge these compounds on evidence, not marketing. Tesamorelin has FDA approval, controlled human trials, and a defined injection protocol for one specific condition. 5-Amino-1MQ has an appealing oral format and interesting mouse data but no human safety record whatsoever.
5-Amino-1MQ and tesamorelin are not interchangeable, and neither one is a general-purpose weight loss drug. Anyone considering either should treat the decision as a medical one and consult a licensed healthcare professional first.
Frequently Asked Questions
Is 5-Amino-1MQ the same as tesamorelin?
No. 5-Amino-1MQ is a small-molecule NNMT inhibitor, while tesamorelin is a synthetic GHRH peptide. They work on completely different pathways, and only tesamorelin has FDA approval for any human use.
Which one is better for fat loss?
Tesamorelin is the only one of the two with FDA approval, and that approval covers visceral fat reduction specifically in adults with HIV-associated lipodystrophy. 5-Amino-1MQ has only rodent data, so no human comparison between the two exists.
Does 5-Amino-1MQ have to be injected?
No. 5-Amino-1MQ is most commonly sold as oral capsules or powder, and injectable versions exist but have no established human pharmacokinetic data. Tesamorelin, by contrast, is only available as a subcutaneous injection.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.